Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forVermont

Map
Vermont
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$1.2 million
to Vermont research institutions
Vermont

Neglected diseases in Vermont

Chikungunya cases
Chikungunya cases
4
Dengue cases
Dengue cases
19
HIV diagnoses
HIV diagnoses
137
Malaria cases
Malaria cases
29
Tuberculosis cases
Tuberculosis cases
48
West Nile cases
West Nile cases
8
Zika cases
Zika cases
26
Vermont's top USG-funded global health R&D institutions

Vermont's top USG-funded global health R&D institutions

University of Vermont
$1.2 million
Vermont industry in global health R&D

Vermont industry in global health R&D

Mylan
Location(s): St. Albans City
QuantaSpec
Location(s): Burlington, Essex Junction

Vermont's top areas of global health R&D by USG funding

19.5%
Malaria
80.5%
Diarrheal diseases
Global health R&D at work in Vermont
Global health R&D at work in Vermont

The University of Vermont’s Vaccine Testing Center is designing a research platform upon which new treatments for cryptosporidiosis can be tested in humans. Cryptosporidiosis, or crypto for short, is an infection caused by Cryptosporidium, a single-celled intestinal parasite found in soil, food, and water. Crypto is a leading cause of severe diarrhea in infants and young children in low-income countries. It also causes significant illness and death in immunocompromised individuals. No vaccines exist to treat or prevent the infection and there are limited treatment options. In many parts of the world, crypto is associated with poor childhood nutrition and stunted growth. Past work by the center has focused on how crypto contributes to the vicious cycle of diarrhea, infectious diseases, and malnutrition.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Case study photo: PATH/Miguel Alvarez
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In